Table 1.
Clinical characteristics of the patients in the training and validation cohorts.
| Variables | Training cohort (N=286) | Validation cohort (N=453) | P-value | ||
|---|---|---|---|---|---|
| No. | % | No. | % | ||
| Sex | 0.650 | ||||
| Female | 87 | 37.50% | 145 | 62.50% | |
| Male | 199 | 39.25% | 308 | 60.75% | |
| Age(years), median(IQR) | 57(50–65) | 58(50–65) | |||
| Age(years) | 0.805 | ||||
| <60 | 163 | 39.09% | 254 | 60.91% | |
| ≧60 | 123 | 38.20% | 199 | 61.80% | |
| Tumor size(cm) | 0.051 | ||||
| <4 | 107 | 43.67% | 138 | 56.33% | |
| ≧4 | 179 | 36.23% | 315 | 63.77% | |
| Tumor location | 0.436 | ||||
| Cardia | 119 | 40.61% | 174 | 59.39% | |
| Body | 61 | 41.78% | 85 | 58.22% | |
| Antrum | 95 | 35.85% | 170 | 64.15% | |
| Whole | 11 | 31.43% | 24 | 68.57% | |
| Differentiation status | 0.195 | ||||
| Well+Moderate | 54 | 43.90% | 69 | 56.10% | |
| Poor and undifferentiated | 232 | 37.66% | 384 | 62.34% | |
| Lauren type | 0.019 | ||||
| Intestinal type | 111 | 44.58% | 138 | 55.42% | |
| Diffuse or mixed type | 175 | 35.71% | 315 | 64.29% | |
| CEA | 0.221 | ||||
| Normal | 215 | 37.52% | 358 | 62.48% | |
| Elevated | 71 | 42.77% | 95 | 57.23% | |
| CA199 | 0.001 | ||||
| Normal | 240 | 41.88% | 333 | 58.12% | |
| Elevated | 46 | 27.71% | 120 | 72.29% | |
| Depth of invasion | 0.035 | ||||
| T1 | 7 | 43.75% | 9 | 56.25% | |
| T2 | 30 | 52.63% | 27 | 47.37% | |
| T3 | 84 | 42.00% | 116 | 58.00% | |
| T4a | 141 | 34.14% | 272 | 65.86% | |
| T4b | 24 | 45.28% | 29 | 54.72% | |
| Lymph node metastasis | 0.928 | ||||
| N0 | 59 | 36.65% | 102 | 63.35% | |
| N1 | 58 | 40.00% | 87 | 60.00% | |
| N2 | 58 | 36.94% | 99 | 63.06% | |
| N3a | 76 | 40.00% | 114 | 60.00% | |
| N3b | 35 | 40.70% | 51 | 59.30% | |
| Stage | 0.741 | ||||
| II | 102 | 37.92% | 167 | 62.08% | |
| III | 184 | 39.15% | 286 | 60.85% | |
| Chemotherapy | 0.456 | ||||
| No | 152 | 40.00% | 228 | 60.00% | |
| Yes | 134 | 37.33% | 225 | 62.67% | |